Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company that leverages new insights into progranulin and lysosomal biology to develop drugs aimed at altering the progression of neurodegenerative diseases. Arkuda's lead compound aims to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically defined subtype of frontotemporal dementia caused by autosomal dominant mutations in the GRN gene.